Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K35/76

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/108951USE OF ANNEXIN V TO IMPROVE THE PURITY, SOLUBILITY AND LONG-TERM STABILITY OF PHAGE SUSPENSIONS
WO 27.05.2022
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No PCT/US2021/059580 Applicant THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Inventor BLANKENBERG, Francis Gerard
Methods are provided for the prevention of aggregation, simple purification stabilization and preservation of phage preparations for the use of treating bacterial infections.
2.WO/2022/109341COMPOUNDS FOR TREATMENT OF OSTEOARTHRITIS
WO 27.05.2022
Int.Class A61K 35/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
Appl.No PCT/US2021/060201 Applicant DORIAN THERAPEUTICS, INC. Inventor ADORNO, Maddalena
The present disclosure relates to methods of treating osteoarthritis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a USP16 inhibitor.
3.WO/2022/107705NEW GENE RECOMBINANT VACCINIA VIRUS AND UTILIZATION THEREOF
WO 27.05.2022
Int.Class C12N 15/24
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
19Interferons; Lymphokines; Cytokines
24Interleukins
Appl.No PCT/JP2021/041825 Applicant NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY Inventor NAKAMURA Takafumi
Provided are a vaccinia virus into which a therapeutic gene has been introduced as an exogenous gene, and a therapeutic composition containing said vaccinia virus. The vaccinia virus comprises at least one immune regulating gene as an exogenous gene.
4.WO/2022/107853LOW-DOSE HEPATOCYTE GROWTH FACTOR GENE THERAPY FOR DIABETES
WO 27.05.2022
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Appl.No PCT/JP2021/042463 Applicant KAGOSHIMA UNIVERSITY Inventor KOSAI, Ken-ichiro
The present invention provides an agent for protecting and regenerating pancreatic beta cells in a mammal having diabetes, the agent containing a recombinant viral vector that expresses hepatocyte growth factor (HGF), wherein the agent is characterized by being administered in a dose of 1010-1012 virus particles (vp)/kg body weight, and by the virus vector including a nucleic acid that encodes HGF downstream of a promoter having transcription activity capable of yielding a therapeutically effective HGF level in the blood at said dose.
5.WO/2022/109503RECOMBINANT ONCOLYTIC VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS
WO 27.05.2022
Int.Class A61K 35/761
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
761Adenovirus
Appl.No PCT/US2021/060669 Applicant DEVACELL, INC. Inventor ORTAC, Inanc
Provided herein are recombinant viruses and artificially coated delivery systems, and methods of use.
6.WO/2022/108120MODIFIED HTERT PROMOTER FOR REGULATING CANCER CELL-SPECIFIC GENE EXPRESSION AND ANTI-TUMOR ADENOVIRUS CONTAINING SAME
WO 27.05.2022
Int.Class C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
Appl.No PCT/KR2021/014180 Applicant CURIGIN CO.,LTD. Inventor PARK, Seong Hoon
The present invention relates to a modified hTERT promoter for regulating cancer cell-specific gene expression and an oncolytic adenovirus comprising same. The modified hTERT promoter of the present invention increases the cancer-specific transcriptional activity of a target gene compared to the case where a wild-type hTERT promoter is used, and when the modified hTERT promoter is used for an oncolytic adenovirus, the tumor-killing effect is excellent compared to the case where an adenovirus is prepared using the wild-type hTERT promoter.
7.WO/2022/100898MIR-375- AND MIR-1-REGULATED COXSACKIEVIRUS B3 HAS NO PANCREAS AND HEART TOXICITY BUT STRONG ANTITUMOR EFFICIENCY IN COLORECTAL CARCINOMAS
WO 19.05.2022
Int.Class A61K 35/768
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
768Oncolytic viruses not provided for in groups A61K35/761-A61K35/76697
Appl.No PCT/EP2021/071767 Applicant TECHNISCHE UNIVERSITÄT BERLIN Inventor FECHNER, Henry
The present invention related to an infectious complementary DNA (cDNA) construct characterized in that the cDNA comprises: - the cDNA of the CVB3 genomic RNA sequence of a Coxsackievirus B3 (CVB3); - at least one or more microRNA target sequences (miR-TS), which are complementary to one or more microRNAs having tissue-specific expression pattern, wherein the at least one or more miR-TS are integrated immediately adjacent of the 5´UTR and/or the 3´UTR of the CVB3 protein coding sequence.
8.20220154150ARTIFICIAL VIRUS PRESENTING CELLS
US 19.05.2022
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No 17550958 Applicant Diagnologix, LLC Inventor Yu-Tsueng LIU

A method for ex vivo transduction of biomolecules from viruses, viral vectors or virus-like particles into target cells and microbubbles for use in this method. A quantity of viruses, viral vectors or virus-like particles and target cells are bound to flexible lipid shell microbubbles, bringing these into close proximity to each other that allows viral transduction, transferring biomolecules from the viruses, viral vectors or virus-like particles into the target cells while the viruses, viral vectors or virus-like particles and the target cells are bound to the microbubbles.

9.WO/2022/101916FUSOBACTERIUM BACTERIOPHAGE AND USES THEREOF
WO 19.05.2022
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No PCT/IL2021/051350 Applicant BIOMX LTD. Inventor ZELCBUCH, Lior Moshe
A method of treating a disease associated with Fusobacterium nucleatum infection in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of at least one isolated bacteriophage capable of infecting a Fusobacterium nucleatum bacterial species, wherein said at least one bacteriophage has a genomic nucleic acid sequence at least 85 % identical to the nucleic acid sequence as set forth in SEQ ID NOs: 1-7 or 15-20. Compositions for treating the disease are also disclosed.
10.WO/2022/100746BISPECIFIC SINGLE-CHAIN ANTIBODY, ANTIBODY-LOADED RECOMBINANT ONCOLYTIC VIRUS, AND VIRUS COMBINATION
WO 19.05.2022
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
Appl.No PCT/CN2021/130773 Applicant BINHUI BIOPHARMACEUTICAL CO., LTD. Inventor LIU, Binlei
The present invention provides a bispecific single-chain antibody BiTEs-PD-L1 capable of simultaneously binding to CD3 and PD-L1 on the surface of a tumor cell, an antibody-loaded recombinant oncolytic virus, and a virus combination. When BiTEs-PD-L1 enters a human body and binds to T cells, the T cells can be effectively activated, and the T cells are guided to kill tumor cells.